ISRCTN71342421已完成未知
The ‘DR-EAM’ study – (Type 2) Diabetes weight Reduction - Evaluation of App coaching Model
niversity of Westminster0 个研究点目标入组 250 人开始时间: 2021年6月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Minimum age of 18 years
- •2. Maximum age of 65 years
- •3. Male or female
- •4. Minimum BMI of 27kg/m² (adjusted to 25kg/m² in people of South Asian or Chinese origin)
- •BMI <45kg/m²
- •5. T2DM diagnosed at any time
- •6. HbA1c eligibility, most recent value, which must be within 12 months:
- •6.1. HbA1c = 43 mmol/mol if on oral diabetes medication or GLP-1
- •6.2. HBA1c <108 mmol/mol - If HbA1c 90-108 mmol/mol, the value must be within 3 months of referral
- •7. On, or about to start, a second-line diabetes-related oral medication or GLP-1 (metformin is first-line)
- •8. Access to blood glucose monitoring equipment if on a sulphonylurea prior to referral
- •9. Ability to speak, read and receive care in English
- •10. Access to and willing to use an iOS or Android smartphone for the duration of the intervention
排除标准
- •1. T2DM either diet-controlled alone, or on metformin alone
- •2. Current insulin use
- •3. Pregnant or breastfeeding or considering pregnancy during next 6 months
- •4. Significant physical comorbidities:
- •4.1. Active cancer
- •4.2. Myocardial infarction or stroke within previous 6 months
- •4.3. Severe heart failure defined as equivalent to the New York Heart Association grade 3 (NYHA)
- •4.4. Recent eGFR <30 mls/min/1.73 m²
- •4.5. Active live disease (except for NAFLD), or a history of hepatoma, or <6 months of onset of acute hepatitis
- •4.6. Severe angina, cardiac arrhythmia including atrial fibrillation or prolonged QT syndrome
- •5. Active substance use disorder/eating disorder
- •6. Porphyria
- •7. Weight loss >5% body weight within last 6 months or on current weight management programme or had/awaiting bariatric surgery (unless willing to come off waiting list)
- •8. Health professional assessment that the person is unable to understand or meet the demands of the treatment programme and/or monitoring requirements, which may include Learning disabilities
- •9. Taking monoamine-oxidase inhibitor medication
- •10. Taking warfarin
- •11. Taking varenicline (smoking cessation medication)
- •12. Unstable retinopathy or lack of retinal screening in the last year
- •13. Active/investigation for gastric or duodenal ulcers
- •14. People currently participating in another clinical trial
研究者
相似试验
进行中(未招募)
不适用
The DR-EAM Type 2 Diabetes StudyType 2 DiabetesNCT05626842Oviva UK Ltd197
已完成
4 期
The effect of weight loss on Type 2 Diabetes: a prospective randomized controlled trial of best practice medical management versus the placement of the Lap-Band System on HbA1c concentration.Metabolic and Endocrine - DiabetesType 2 DiabetesACTRN12605000159651Centre for Obesity Research and Education (CORE)60
招募中
不适用
Study on diabetes remission using weight management program for obesity and type 2 diabetestype 2 diabetesJPRN-UMIN000035237Asama General Hospital40
已完成
不适用
Weight Loss and Type 2 Diabetes: A prospective randomised controlled trial intervention study of best practice medical management versus the additional placement of the Lap-Band System in overweight patientsDiabetes Type 2Metabolic and Endocrine - DiabetesDiet and Nutrition - ObesityObesityACTRN12609000286246Monash University38
招募中
不适用
Prospective randomised controlled trial comparing the efficacy of laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for the management of type 2 diabetes mellitus in obese patientsType 2 diabetes mellitusMetabolic and Endocrine - DiabetesSurgery - Surgical techniquesDiet and Nutrition - ObesityObesityACTRN12611000751976Waitemata District Health Board106
